Proactive Investors - Run By Investors For Investors

Medlab Clinical eyes cost savings following receipt of SME status in Europe

Drug registration of NanaBis in Europe is a key part of Medlab’s plans and the SME qualification allows it to start the process.
EU symbol
Medlab recently completed successful stage 1 human trial of NanaBis on cancer patients

Medlab Clinical Ltd’s (ASX:MDC) European subsidiary has received formal SME (small or medium-sized enterprise) qualification from European Medicines Agency (EMA).

EMA is the European equivalent to the Australian TGA and the US FDA. As part of the registration, this allows MDC to apply for scientific advice, drug evaluation and registration of NanaBis.

It also provides MDC with the opportunity to obtain fee reductions up to 90% in the process.

NanaBi is a cannabis-based medicine which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

 

Medlab chief executive officer Dr Sean Hall said: “This is a significant milestone for MDC. Drug registration of NanaBi is key part of the company’s plans and this qualification allows us to start the process into Europe.

“Drug evaluation and registration fees with the various agencies are expensive, but at the same time, a much needed and real cost in bringing a drug to market and we welcome the opportunity obtain fee reductions and as a result significant savings.

“Personally, I would like to thank EMA for their collaborative approach in this regard, and very much look forward to escalating the NanaBis evaluation with EMA as we move closer to an approved drug in the EU.”

READ: Medlab Clinical proceeding to stage 2 for cannabis cancer trial

In late October 2018, Medlab successfully completed stage 1 of the NanaBis human trial on cancer patients at Royal North Shore Hospital.

The trial is progressing as planned and currently in stage II of the ethics approved trial.

READ: Medlab Clinical receives preliminary results from NanoStat™ trial

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

A cannabis plant shown next to an oil-based product
18:30
THC is executing medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.
cannabis plant
March 08 2019
The Vancouver company's recent move into Jamaica, which covers the acquisition of 145 acres of cultivation property, will pave the way for the development of cannabis brands for the island nation
medical cannabis concept
February 10 2019
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use